At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 335 enrolled
Drug / intervention
T-2345 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multicenter, Parallel-Group, Observer-Masked, Phase 3 Study to Compare the Safety and Efficacy of T-2345 Ophthalmic Solution to Xalatan (Latanoprost 0.005%) in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
In Brief
A Phase 3 clinical trial evaluating T-2345 and Xalatan for Primary Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 335 participants across 1 site.
Detailed Summary
This is a Phase 3 study to evaluate the safety and efficacy of T-2345 dosed to one of both eyes once daily for 84 days compared to Xalatan dosed to one of both eyes once daily for 84 days in patients with elevated eye pressure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Open Angle Glaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
First PostedFeb 2014
Primary CompletionJan 2015
TodayJul 2026
First PostedFeb 11, 2014
Enrollment StartJan 1, 2014
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 12.4 years ago
Interventions
T-2345drug
T-2345 Ophthalmic Solution
Xalatandrug
Xalatan (latanoprost 0.005% ophthalmic solution)